Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
The mechanistic role of the AIM2 inflammasome in combined radiation-immunotherapy
EF 2018-19
Résumé
Immunotherapy has emerged as a fourth pillar for cancer treatment but success has been limited as a treatment on its own. To improve immunotherapy success, clinicians are beginning to combine it with other treatment modalities, like radiotherapy, for solid tumours. Our group is primarily interested in molecular mechanisms by which immunotherapy and radiotherapy combine to enhance treatment. Recent studies in our lab have shown that molecules that normally respond to viral infections, like cGAS-STING and AIM2, initiate inflammatory signalling that can stimulate the immune system. In this project we will determine how AIM2 activates the inflammatory response post-radiotherapy, and how this drives recruitment of immune cells to tumours. The ultimate goal of this project is to expand the utility of immunotherapy to more patients, as it sets the stage for using AIM2 and cGAS-STING as a prognostic biomarker to identify patients who will respond most favourably to combination radiotherapy-immunotherapy treatment.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
411243
Name
Ha Cindy
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The mechanistic role of the AIM2 inflammasome in combined radiation-immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Immunotherapy; Abscopal Effect; Cancer; Cancer Genetics; Cell Biology; Cell Signaling; Dna Damage; Genetics; Immunology; Radiotherapy
Abstract
Immunotherapy has emerged as a fourth pillar for cancer treatment but success has been limited as a treatment on its own. To improve immunotherapy success, clinicians are beginning to combine it with other treatment modalities, like radiotherapy, for solid tumours. Our group is primarily interested in molecular mechanisms by which immunotherapy and radiotherapy combine to enhance treatment. Recent studies in our lab have shown that molecules that normally respond to viral infections, like cGAS-STING and AIM2, initiate inflammatory signalling that can stimulate the immune system. In this project we will determine how AIM2 activates the inflammatory response post-radiotherapy, and how this drives recruitment of immune cells to tumours. The ultimate goal of this project is to expand the utility of immunotherapy to more patients, as it sets the stage for using AIM2 and cGAS-STING as a prognostic biomarker to identify patients who will respond most favourably to combination radiotherapy-immunotherapy treatment.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ha, Cindy
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~